Head to head
Trulieve Cannabis vs Takeda Pharmaceutical
Side-by-side on the measures that matter, with a plain-English read. Full detail: TRLV · TAK
TRLV
Trulieve Cannabis
8.68-7.17%
1-year price shape — +81% over the period
Quant Rating D · 95/100
vs
TAK
Takeda Pharmaceutical
21.77+1.68%
1-year price shape — +57% over the period
Quant Rating C · 90/100
1-year performance, rebased to 100
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
| TRLV | TAK | |
|---|---|---|
| Snapshot | ||
| Sector | Drug Manufacturers - Specialty & Generic | -- |
| Last price | 8.68 | 21.77 |
| Change today | -7.17% | +1.68% |
| 1-year return | +81.5% | +57.5% |
| Market cap | $1.68B | $69.76B |
| 52-week range | 5.00 – 13.28 | 13.92 – 22.07 |
| Valuation | ||
| P/E (TTM) | -3.76 | 311.00 |
| P/E percentile, own 5-yr range | 35th | 100th |
| P/B | 2.17 | 1.50 |
| Dividend yield | 0.00% | 1.44% |
| Profitability & growth | ||
| EPS (TTM) | -0.61 | -0.30 |
| Net profit (TTM) | $-117.75M | $-970.94M |
| Revenue (TTM) | $1.08B | $4.69T |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | -20.1% | +6.7% |
| Gross margin | 60.6% | 65.8% |
| Operating margin | 12.2% | 14.3% |
| Net margin | -41.2% | 0.9% |
| Free cash flow (TTM) | $186.22M | $433.95B |
| Provider cash-flow period date | 2026-06-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 28.6% | 51.3% |
| Insider activity (12mo) | 33 buy / 12 sell | 19 buy / 31 sell |
| Short interest (% of float) | 2.0% | 0.1% |
| Analyst consensus | 100% buy (3) | 100% buy (1) |
| Analyst price target | $18 (+107%) | $50 (+132%) |
| StockVane view | ||
| StockVane Quant Rating | D (95) | C (90) |
| Company | ||
| Employees | 5,000 | 47,029 |
| Founded | 1940 | 1781 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.